19 January 2016 in Biotechnology Journal
5 September 2023 in Journal of Toxicology and Environmental Health, Part A
Quercetin (QUE) belonging to the flavonoid class is a common phytochemical present in the daily diet of some individuals. Quercetin is an important source of free radical scavengers. This property makes this flavonoid a reliable antioxidant with the following properties: anti-inflammatory, anti-diabetic, antimicrobial and anti-carcinogenic. Sodium butyrate (NaBu) acts as a histone deacetylase inhibitor (HDACi) and is known to regulate apoptosis in cancer cells. Combining natural flavonoids such as QUE with different substances may synergistically enhance their anti-carcinogenic capacity. Thus, the aim of this study was to examine the combined treatment effects of QUE and NaBu in hormone-sensitive breast cancer cells in vitro. MCF-7 breast cancer cells were treated with QUE alone, NaBu alone, as well as QUE and NaBu combined to determine the following: cell proliferation, levels of protein annexin A5 (ANXA5) and reactive oxygen species (ROS), mRNA protein expression, as well as cell and nuclear morphology. Data demonstrated that either QUE or NaBu alone inhibited cell proliferation, and reduced levels protein ANXA5, ROS and mRNA protein expression, The combination of QUE and NaBu produced a significant synergistic inhibitory effect compared to treatment groups of QUE or NaBu alone. In conclusion, our findings showed that the combination treatment of QUE and NaBu may constitute a promising therapeutic approach to breast cancer treatment but this needs further molecular and in vivo investigations.
15 June 2022 in International Journal of Peptide Research and Therapeutics
28 February 2023 in Acta Medica Nicomedia
Objective: The difficulties experienced in the treatment of prostate cancer and the excess of side effects due to chemotherapy have brought the search for alternative treatment strategies. In recent studies, it is known that Rutin (RUT) has an anti-cancer effect on cancer cells. Our study aimed to determine the effects of RUT on epithelial-mesenchymal transition (EMT) in prostate cancer cells, for the first time. Methods: The anticancer activity of RUT in prostate cancer cells (PC-3) was determined by WST-1, Annexin V ELISA, DAPI and Acridine Orange staining, and the anti-cancer and anti-metastatic properties of RUT were evaluated with the Scratch Assay test. The mRNA expression level of Bax, Bcl-2, Snail, Twist, Vimentin and E-cadherin genes was determined by RT-PCR. Results: PC-3 cells were treated with RUT (500, 750, 1000, 1500 µM) for 24 and 48 hours. The viability rates decreased with increasing RUT concentration depending on dose and time (p
31 August 2024 in İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi
Aim: Breast cancer remains a significant cause of mortality worldwide, necessitating the development of innovative therapeutic approaches. Epigenetic and epitranscriptomic regulation have emerged as promising avenues for novel treatments. Sodium Butyrate (NaB) and Meclofenamic Acid (MFA) have gained attention for their respective roles in epigenetic and epitranscriptomic modulation. NaB, a histone deacetylase inhibitor, serves as a critical regulator of chromatin remodeling and gene expression. MFA has been identified to be a potent inhibitor of the FTO enzyme. This inhibitory potential marks its role in epitranscriptomic regulation. This study aimed to investigate the potential effects of MFA and NaB, individually and in combination, on the MCF7 breast cancer cell line. Method: In order to investigate the cytotoxic and apoptotic effects of the combination treatment of MFA and NaB, cell viability assay, Annexin V analysis and Acridine Orange/DAPI staining were executed. Results: The results revealed that the combination treatment unexpectedly exhibited antagonistic effects. This was evidenced by a remarkable increase in cell viability and a decreased apoptotic response compared to individual treatments. The strongest antagonistic effect was observed when the cells were treated with 100 μM MFA and 2 mM NaB for a period of 48 hours (CI = 88.3). Conclusion: This study, for the first time, sheds light on the complex interaction between meclofenamic acid and sodium butyrate that reveals an unexpected antagonistic effect on MCF7 breast cancer cells. These findings challenge conventional concepts of synergistic interactions and underscore the complexity of drug combinations in breast cancer treatment.